Table 2.

Transition probabilities (12 and 24 months) for incident HPV16, 18, 31, 45, 52, and 58a infected CIN1 lesions following adjudication of CIN lesions positive for multiple HPV types

Persisting as CIN1/HPVClearing HPVCIN2CIN3
HPV16 (n = 38)
 12 Months42.9 (19.3–67.1)34.9 (11.7–58.8)11.5 (0.0–29.3)10.7 (0.0–27.5)
 24 Months10.0 (0.0–43.9)43.8 (18.2–70.2)27.5 (0.0–61.0)18.7 (0.0–43.5)
HPV18 (n = 18)
 12 Months60.1 (32.4–85.7)30.0 (6.3–55.0)9.8 (0.0–33.7)0.0 (-)
 24 MonthsNAbNAbNAbNAb
HPV31 (n = 28)
 12 Months17.1 (0.0–55.1)67.4 (29.3–100.0)15.4 (0.0–51.6)0.0 (-)
 24 Months10.5 (0.0–49.4)74.0 (33.4–100.0)15.4 (0.0–51.6)0.0 (-)
HPV45 (n = 9)
 12 Months36.6 (0.0–76.2)63.3 (23.8–100.0)0.0 (-)0.0 (-)
 24 MonthsNAbNAbNAbNAb
HPV52 (n = 22)
 12 Months26.3 (0.0–75.0)50.1 (11.1–88.2)23.5 (0.0–79.4)0.0 (-)
 24 Months15.5 (0.0–70.0)60.9 (14.3–100.0)23.5 (0.0–79.4)0.0 (-)
HPV58 (n = 16)
 12 Months54.2 (15.8–86.7)45.7 (12.9–83.8)0.0 (-)0.0 (-)
 24 MonthsNAbNAbNAbNAb
HPV59 (n = 13)
 12 Monthsc34.0 (0.0–87.5)65.9 (12.5–100.0)0.0 (-)0.0 (-)
 24 MonthsNAbNAbNAbNAb

NOTE: All values are given in % (95% CI).

  • aData are not reported in the table for CIN1 lesions positive for HPV33 (n = 3) or HPV35 (n = 5) due to the small numbers of observations; however, none of these individuals were observed to transition to CIN2 or 3 lesions positive for these types within the available follow-up.

  • bIndividual(s) with longest follow-up time(s) were censored before 24 months postincident CIN1.

  • cThe longest available follow-up time for HPV59-positive CIN1 lesions was 11 months.